ATYR PE Ratio & Valuation, Is ATYR Overvalued

Historical Valuation

aTyr Pharma Inc (ATYR) is now in the Fair zone, suggesting that its current forward PS ratio of 68.15 is considered Fairly compared with the five-year average of -2.81. The fair price of aTyr Pharma Inc (ATYR) is between -- to -- according to relative valuation method.

Relative Value

Fair Zone

-----

Current Price：0.94

Fair

P/E

EV/EBITDA

EV/EBIT

P/S

P/OCF

P/FCF

Trailing

Forward

Unlock 5-Year Valuation Change

Is aTyr Pharma Inc (ATYR) at a historical peak or a rare bargain? Access the full 5-year trend to find out.

Unlock Now

aTyr Pharma Inc (ATYR) has a current Price-to-Book (P/B) ratio of 0.93. Compared to its 3-year average P/B ratio of 2.30, the current P/B ratio is approximately -59.63% higher. Relative to its 5-year average P/B ratio of 1.93, the current P/B ratio is about -51.88% higher. aTyr Pharma Inc (ATYR) has a Forward Free Cash Flow (FCF) yield of approximately -84.69%. Compared to its 3-year average FCF yield of -38.90%, the current FCF yield is approximately 117.72% lower. Relative to its 5-year average FCF yield of -37.31%, the current FCF yield is about 126.97% lower.

Competitors Valuation Multiple

AI Analysis

The average P/S ratio for ATYR competitors is 14.87, providing a benchmark for relative valuation. aTyr Pharma Inc Corp (ATYR.O) exhibits a P/S ratio of 68.15, which is 358.38% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.

P/E

P/S

EV/EBITDA

EV/EBIT

Earnings Growth

Market Cap

Performance Decomposition

AI Analysis

Market capitalization of ATYR increased by 0.00% over the past 1 year(s). The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.

The secondary factor is the Unknown, contributed 0.00% to the performance.

Overall, the performance of ATYR in the past 1 year(s) is driven by Unknown.

People Also Watch

Frequently Asked Questions

Is ATYR currently overvalued or undervalued?

What is aTyr Pharma Inc (ATYR) fair value?

ATYR's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. The fair price of aTyr Pharma Inc (ATYR) is between to according to relative valuation method.

How does ATYR's valuation metrics compare to the industry average?

The average P/S ratio for ATYR's competitors is 14.87, providing a benchmark for relative valuation. aTyr Pharma Inc Corp (ATYR) exhibits a P/S ratio of 68.15, which is 358.38% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.

What is the current P/B ratio for aTyr Pharma Inc (ATYR) as of Mar 11 2026?

As of Mar 11 2026, aTyr Pharma Inc (ATYR) has a P/B ratio of 0.93. This indicates that the market values ATYR at 0.93 times its book value.

What is the current FCF Yield for aTyr Pharma Inc (ATYR) as of Mar 11 2026?

As of Mar 11 2026, aTyr Pharma Inc (ATYR) has a FCF Yield of -84.69%. This means that for every dollar of aTyr Pharma Inc's market capitalization, the company generates -84.69 cents in free cash flow.

What is the current Forward P/E ratio for aTyr Pharma Inc (ATYR) as of Mar 11 2026?

As of Mar 11 2026, aTyr Pharma Inc (ATYR) has a Forward P/E ratio of -1.33. This means the market is willing to pay $-1.33 for every dollar of aTyr Pharma Inc's expected earnings over the next 12 months.

What is the current Forward P/S ratio for aTyr Pharma Inc (ATYR) as of Mar 11 2026?

As of Mar 11 2026, aTyr Pharma Inc (ATYR) has a Forward P/S ratio of 68.15. This means the market is valuing ATYR at $68.15 for every dollar of expected revenue over the next 12 months.

ATYR Valuation